These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 2184514)
41. Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients. A double-blind, multicenter placebo-controlled study. The Candida Esophagitis Multicenter Italian Study (CEMIS) Group. Barbaro G; Barbarini G; Di Lorenzo G Chest; 1996 Dec; 110(6):1507-14. PubMed ID: 8989069 [TBL] [Abstract][Full Text] [Related]
42. Clinical and mycological responses to fluconazole and fluconazole MIC in oropharyngeal candidiasis in HIV-infected patients. Bussaratid V; Tansupasawasdikul S; Simpson A; Pitisuttithum P; Phonrat B; Howe P; White NJ J Med Assoc Thai; 2002 Jul; 85(7):757-64. PubMed ID: 12296406 [TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. Slavin MA; Osborne B; Adams R; Levenstein MJ; Schoch HG; Feldman AR; Meyers JD; Bowden RA J Infect Dis; 1995 Jun; 171(6):1545-52. PubMed ID: 7769290 [TBL] [Abstract][Full Text] [Related]
44. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Schuster MG; Edwards JE; Sobel JD; Darouiche RO; Karchmer AW; Hadley S; Slotman G; Panzer H; Biswas P; Rex JH Ann Intern Med; 2008 Jul; 149(2):83-90. PubMed ID: 18626047 [TBL] [Abstract][Full Text] [Related]
45. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. De Wit S; Weerts D; Goossens H; Clumeck N Lancet; 1989 Apr; 1(8641):746-8. PubMed ID: 2564563 [TBL] [Abstract][Full Text] [Related]
46. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Kicklighter SD; Springer SC; Cox T; Hulsey TC; Turner RB Pediatrics; 2001 Feb; 107(2):293-8. PubMed ID: 11158461 [TBL] [Abstract][Full Text] [Related]
47. Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot study. Vazquez JA; Hidalgo JA; De Bono S HIV Clin Trials; 2000; 1(3):23-9. PubMed ID: 11590502 [TBL] [Abstract][Full Text] [Related]
49. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis. Arikan S; Akova M; Hayran M; Ozdemir O; Erman M; Gür D; Unal S Clin Infect Dis; 1998 Apr; 26(4):903-8. PubMed ID: 9564473 [TBL] [Abstract][Full Text] [Related]
50. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. Schaffner A; Schaffner M J Infect Dis; 1995 Oct; 172(4):1035-41. PubMed ID: 7561177 [TBL] [Abstract][Full Text] [Related]
51. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species. Khedri S; Santos ALS; Roudbary M; Hadighi R; Falahati M; Farahyar S; Khoshmirsafa M; Kalantari S Lett Appl Microbiol; 2018 Oct; 67(4):392-399. PubMed ID: 30019443 [TBL] [Abstract][Full Text] [Related]
52. Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome. Akova M; Akalin HE; Uzun O; Hayran M; Tekuzman G; Kansu E; Aslan S; Telatar H Clin Infect Dis; 1994 Mar; 18(3):298-304. PubMed ID: 8011807 [TBL] [Abstract][Full Text] [Related]
53. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530 [TBL] [Abstract][Full Text] [Related]
54. Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Nicolatou-Galitis O; Velegraki A; Sotiropoulou-Lontou A; Dardoufas K; Kouloulias V; Kyprianou K; Kolitsi G; Skarleas C; Pissakas G; Papanicolaou VS; Kouvaris J Support Care Cancer; 2006 Jan; 14(1):44-51. PubMed ID: 15947956 [TBL] [Abstract][Full Text] [Related]
55. Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study. Barbaro G; Barbarini G; Di Lorenzo G Endoscopy; 1995 Jun; 27(5):377-83. PubMed ID: 7588352 [TBL] [Abstract][Full Text] [Related]
56. Prophylaxis of oral candidiasis with clotrimazole troches. Owens NJ; Nightingale CH; Schweizer RT; Schauer PK; Dekker PT; Quintiliani R Arch Intern Med; 1984 Feb; 144(2):290-3. PubMed ID: 6365008 [TBL] [Abstract][Full Text] [Related]
57. Efficacy of melaleuca oral solution for the treatment of fluconazole refractory oral candidiasis in AIDS patients. Jandourek A; Vaishampayan JK; Vazquez JA AIDS; 1998 Jun; 12(9):1033-7. PubMed ID: 9662200 [TBL] [Abstract][Full Text] [Related]
58. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531 [TBL] [Abstract][Full Text] [Related]
59. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis. Ziakas PD; Kourbeti IS; Mylonakis E Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393 [TBL] [Abstract][Full Text] [Related]